Streetbeat News

Regulatory

SGEN

Seagen Inc. (NASDAQ:SGEN) presented initial Phase 2 data for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma at the Society for Immunotherapy of Cancer Annual Meeting. The company also shared preclinical data for a novel antibody-drug conjugate SGN-35T. The combination of ADCETRIS and a PD-1 inhibitor showed promising results, supporting continued research. Seagen plans to begin enrolling patients in a phase 1 clinical trial for SGN-35T soon.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) has presented positive safety and feasibility data from a Phase 1 trial of its investigational class C toll-like receptor-9 (TLR9) agonist, SD-101, for pancreatic adenocarcinoma at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. The data from the PERIO-03 clinical trial indicates that the Pressure-Enabled Drug Delivery (PEDD) method resulted in modulation of the tumor microenvironment. The trial revealed no serious grade 3/4 adverse events related to treatment in three patients who received SD-101 via retrograde venous infusion PEDD at the lowest dose level.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:11 pm

XAIR

Beyond Cancer, an affiliate of Beyond Air, Inc. (NASDAQ:XAIR), presented first-in-human clinical data for ultra-high concentration nitric oxide (UNO) therapy in solid tumors at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The Phase 1 study showed promising safety profile and clear evidence of immune system activation. Additional Phase 1 data for UNO is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:10 pm

MOLN

Molecular Partners AG (NASDAQ:MOLN) has presented positive data from its ongoing Phase 1 trial of MP0317 monotherapy in patients with advanced solid tumors at the 2023 SITC Annual Meeting. The data shows that MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment. The monotherapy also shows a favorable safety profile up to the highest planned doses. The company expects to share final results of this study in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

XRPUSD

Ripple (XRP) saw a 10% surge in its weekly price, followed by significant transfers of XRP tokens to centralized exchanges Bitstamp and Bitso. An unidentified wallet transferred 50 million XRP tokens to these exchanges. Ripple also unlocked 1 billion XRP from its escrow accounts. Meanwhile, Ripple announced partnerships with the National Bank of Georgia for a digital currency project and received approval from the Dubai Financial Services Authority for the use of XRP within the Dubai International Financial Centre.

Portfolio Pulse from Khyathi Dalal

November 03, 2023 | 4:09 pm

XNCR

Xencor has presented preclinical data from multiple XmAb research programs at the SITC Annual Meeting. The company is conducting a Phase 1 study of XmAb808 in patients with advanced solid tumors. Xencor also engineered stabilized, potency-modulated IL-18 cytokines fused to an XmAb heterodimeric Fc domain with Xtend™ Fc technology for longer half-life (IL18-Fc). Further, Xencor's XmAb natural killer cell engagers (NKEs) are multifunctional antibodies that target multiple activating receptors on the surface of NK cells and bind to tumor-associated antigens.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) presented new data on its agenT-797 therapy for solid tumor cancers at the Society for Immunotherapy of Cancer's annual meeting. The therapy showed clinical responses and long-term persistence without toxic pre-conditioning. AgenT-797 is advancing in a randomized phase 2 trial in 2L gastric cancer. The company also plans to launch a randomized phase 2 trial in 2L gastric cancer by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm

SPY

VGK

The US State Department has announced a new weapons package for Ukraine, which will provide up to $125 million of arms and equipment. This move is expected to have geopolitical implications.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm

AFMD

Affimed presented preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, showing that the addition of its innate cell engager (ICE) improves the cytotoxicity of natural killer (NK) and CAR-NK cells. The use of ICE with NK cells eliminates the need for complex and costly manufacturing compared to CAR-NK cells, and offers flexibility to be used with NK cells from different sources.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:06 pm

ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) presented data on its next generation Cloak and Dagger technologies at the Society for Immunotherapy of Cancer Annual Meeting. These technologies are designed to enhance the performance of AlloCAR T cell candidates and control immune rejection. The Cloak technology prevents AlloCAR T cells from being recognized by host T cells, while the Dagger technology arms AlloCAR T cells with a CD70 CAR designed to recognize and deplete CD70-positive host immune cells. The Dagger technology is a feature of ALLO-316, currently being investigated in a Phase 1 study for solid tumors.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:06 pm